For 25 years, RaySearch Laboratories has been creating value by advancing cancer treatment through software innovation. We have the ambition to keep you updated about our performance and other factors contributing to your assessment of RaySearch as an investment.
INVESTOR RELATIONS
Key figures (rolling 12m)
Latest press releases
Year-end report 2025: Record revenue and strong earnings growth despite currency headwinds
The Royal Marsden NHS Foundation Trust uses RayStation for online adaptive treatments with conventional C-arm linacs
Invitation to presentation of RaySearch’s interim report for the fourth quarter of 2025
Financial Calendar
The Share
Subscribe
IR contact
- Carolina Haglund Strömlid
- Head of Investor Relations
- ir@raysearchlabs.com
- +46 (0)70 880 71 73